The draft agreement outlines the Food and Drug Administration’s goals for medical device reviews from 2028 to 2032.
Source: MedTech Dive
You may also like
My Search for a Psychiatric Bed in an Overburdened...
Physicians’ wearable data use hampered by...
Resmed to sell MatrixCare for $490M to private equity...
CVS CEO says Aetna has a handle on medical costs in...
Whistleblower lawsuit accuses Alignment of accounting...
Physicians’ wearable data use hampered by...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.